SUBSCRIBE
SUBSCRIBE
Tyler Patchen

Tyler Patchen

Freelance Writer

Tyler is a journalist with over six years of experience in the world of business journalism. He started his career with the Birmingham Business Journal in Birmingham, Alabama writing about health care, technology, sports business and education. He previously worked as a reporter for Endpoints News and for BioSpace, covering biopharma business and manufacturing. Tyler currently lives in Birmingham, Alabama and holds interests in reading, golf and is also a passionate sports fan. You can reach him at tpatchen94@gmail.com.

Pictured: bluebird bio logo on wall/device, courtesy of Pavlo Gonchar
Business
Bluebird Bio Secures Deal with Large Commercial Payer for Lyfgenia Amid Price Concerns
Despite pricing concerns for bluebird bio’s FDA-approved sickle cell disease gene therapy, the biotech has inked a deal with an unnamed commercial payer “representing approximately 100 million covered lives” in the U.S.
December 15, 2023
 · 
2 min read
 · 
Tyler Patchen
Facade of the FDA's office in Maryland
Policy
FDA Puts Clinical Hold on Three CARsgen Therapeutics CAR-T Candidates
The regulator placed the clinical hold on the Chinese biotech’s trio of CAR-T cell therapy candidates after an inspection of its Durham, North Carolina manufacturing facility.
December 15, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Facade of Moderna's building in Massachusetts
Drug Development
Moderna, Merck Cancer Vaccine-Keytruda Combo Gets Win at Three-Year Mark
The combination of Keytruda and an mRNA vaccine reduced the risk of death or relapse in patients with the most deadly form of skin cancer after three years in a Phase IIb study.
December 14, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Two business professionals in suits shaking hands
Editas and Vertex Ink Deal for Cas9 License for $50M Upfront
The deal follows the FDA approval of Vertex’s gene-editing sickle cell treatment and Editas’ earlier legal battle over rights to the technology.
December 13, 2023
 · 
1 min read
 · 
Tyler Patchen
Pictured: Pfizer's signage outside its office in Canada/iStock, JHVEPhoto
Business
Pfizer’s 2024 Outlook Disappoints Wall Street, Plans $500M in Additional Cost Cuts
The biopharma giant provided full-year 2024 guidance on Wednesday that fell below Wall Street’s expectations, as it continues a cost-cutting effort now up to $4 billion in total.
December 13, 2023
 · 
2 min read
 · 
Tyler Patchen
FDA
Major FDA approvals for Vertex/CRISPR; bluebird gets black box warning and price scrutiny
This week, we discuss the two major FDA approvals for sickle cell from Vertex/CRISPR and bluebird bio; Axcella and the future of long-covid treatments, Vanda’s $100m purchase and AI regulatory developments in Europe.
December 13, 2023
 · 
1 min read
 · 
Lori Ellis
Pictured: Johnson & Johnson Sign/iStock, JHVEPhoto
Drug Development
J&J, Genmab Unveil Darzalex Faspro Data with Eye Toward Earlier Multiple Myeloma Lines
Johnson & Johnson and Genmab revealed the first data from a Phase III study of a Darzalex Faspro-based quadruplet therapy in patients with transplant-eligible newly diagnosed multiple myeloma.
December 13, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Golden Gate Bridge/iStock, bloodua
Headed to JPM? Here Are Some Tips to Make the Most of It
BioSpace spoke with industry professionals about how to make your time in San Francisco valuable.
December 13, 2023
 · 
3 min read
 · 
Tyler Patchen
Pictured: Stack of coins with trading graph/iStock
Tome Biosciences Launches with $213M in Funding, Targets ‘New Era’ of Genomic Medicines
Backed by ARCH Venture Partners and Fujifilm, as well as technology licensed from MIT, Tome is looking to create curative cell and integrative gene therapies.
December 12, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Pfizer's signage at its world headquarters in New York
Deals
Pfizer’s $43B Seagen Buy Clears Regulatory Hurdles, Plans Dec 14 Closing
The companies have received all required regulatory approvals to complete the deal, the largest for the sector in the past three years and the biggest for the hot antibody-drug conjugate market.
December 12, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Regeneron logo on a light brown building
Drug Development
Regeneron Presents Positive Phase II Results for its Lymphoma Drug
The New York-based pharma reported at ASH that odronextamab had an 80% objective response rate, with 73% of patients experiencing a complete response.
December 11, 2023
 · 
2 min read
 · 
Tyler Patchen
Photo shows professional holding box of work-relat
Drug Development
Axcella Health Becomes the Latest Flagship Company to Close its Doors
Another Flagship-founded company is shutting down its operations, according to an SEC filing. Axcella Health, which was focused on the development of a long COVID therapeutic, is no more.
December 8, 2023
 · 
1 min read
 · 
Tyler Patchen
Courtesy of Daiichi Sankyo
Policy
Daiichi Sankyo Reaches $182M Settlement with Novartis in Tafinlar Patent Case
Plexxikon, which was acquired by Daiichi Sankyo, and Novartis have agreed to settle a patent case involving the cancer drug Tafinlar and its sale in the U.S.
December 8, 2023
 · 
1 min read
 · 
Tyler Patchen
Pictured: Mihael Polymeropoulos, CEO, Vanda Pharma
Vanda Buys US, Canadian Rights to J&J’s MS Drug Ponvory in $100M Deal
Under an agreement with Johnson & Johnson’s Actelion Pharmaceuticals, the rights to the multiple sclerosis drug Ponvory in the U.S. and Canada will be transferred to Vanda Pharmaceuticals.
December 8, 2023
 · 
2 min read
 · 
Tyler Patchen
Merck Research Laboratories in South San Francisco, California
Drug Development
Merck’s Keytruda, Anti-TIGIT Combo Fails Phase II NSCLC Trial
A combination of Merck’s experimental anti-TIGIT antibody vibostolimab and anti-PD-1 drug Keytruda failed to hit its endpoints in a mid-stage non-small cell lung cancer study.
December 7, 2023
 · 
2 min read
 · 
Tyler Patchen
Load More